Weight Loss Drug Goes Generic for 3 Billion People

For millions of people struggling with obesity and diabetes, a medication that once cost hundreds of dollars per month is about to become affordable.

This Saturday, Novo Nordisk loses patent protection for semaglutide (sold as Ozempic and Wegovy) in some of the world's most populous countries. Generic versions will launch immediately in India, with China, Canada, Brazil, Turkey, and South Africa following in the coming months.

The numbers tell an incredible story. India and China alone are home to more than 800 million adults who are obese or overweight and 360 million adults with diabetes. Until now, these medications have been accessible almost exclusively to wealthy people in high-income countries.

Argent Wang knows this reality too well. The 31-year-old from Dalian, China currently pays $160 monthly for the drug while managing diabetes complications. When her doctor suggested a different dose at $291 per month, she couldn't afford it. If generics drop to $75 or less, she'll finally have options.

Analysts predict that as competition increases, generic prices could fall to about $15 per month. Compare that to Wegovy's current U.S. price of $349 monthly without insurance. That's a 95% price drop.

Leena Menghaney, a treatment access activist in New Delhi, captured the significance perfectly. "The availability of these drugs, which have been restricted to high-income countries to very wealthy people, will now be democratized by the generics," she said.

Dozens of manufacturers have been racing to produce supplies and win regulatory approvals. Siddharth Mittal, chief executive of Indian manufacturer Biocon, said he's never seen this level of excitement for any drug going off patent.

The Ripple Effect

The impact extends far beyond individual patients. These medications have proven benefits in preventing heart attacks and strokes, not just treating obesity and diabetes.

Public health advocates hope that lower prices will convince national health insurance systems to cover the drugs for their citizens. Currently, most public health systems only cover the medication for diabetes treatment, rejecting coverage for weight loss due to cost.

Lower prices could also bring semaglutide to poorer countries where Novo Nordisk never sought patent protection and where access has been virtually nonexistent.

The generics won't reach the United States and Europe until the early 2030s due to special regulatory protections. However, once generics become available in Canada (where patents expired in January), some U.S. patients may seek to import from Canadian pharmacies.

While the medications aren't perfect (some patients experience nausea, vomiting, or constipation), severe adverse reactions remain rare. For most people, the benefits significantly outweigh the side effects.

What started as a medication accessible only to the wealthy is about to reach billions who need it most.